Skip to main content

Advertisement

SpringerLink
Log in

Landmark Trials in the Surgical Management of Mesothelioma

  • Thoracic Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

The treatment of mesothelioma has evolved slowly over the last 20 years. While surgery as a standalone treatment has fallen out of favor, the importance of multimodality treatment consisting of combinations of chemotherapy, radiotherapy, and surgery have become more common in operable, fit patients. In this review, we discuss trials in surgery, chemotherapy, and radiation that have shaped contemporary multimodality treatment of this difficult malignancy, and we touch on the new and emerging immunotherapeutic and targeted agents that may change the future treatment of this disease. We also review the multimodality treatment regimens, with particular attention to trimodality therapy and neoadjuvant hemithoracic radiation strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Alpert N, van Gerwen M, Taioli E. Epidemiology of mesothelioma in the 21st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28–38. https://doi.org/10.21037/tlcr.2019.11.11.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Ruff K. How Canada changed from exporting asbestos to banning asbestos: the challenges that had to be overcome. Int J Environ Res Publ Health. 2017;14(10):1135. https://doi.org/10.3390/ijerph14101135.

    Article  Google Scholar 

  3. Mazurek JM, Syamlal G, Wood JM, Hendricks SA, Weston A. Malignant mesothelioma mortality: United States, 1999–2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214–8. https://doi.org/10.15585/mmwr.mm6608a3.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, Sorahan T. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716–24. https://doi.org/10.2471/BLT.11.086678.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Kindler HL, Ismaila N, Armato SG III, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(13):1343–73. https://doi.org/10.1200/JCO.2017.76.6394.

    Article  PubMed  Google Scholar 

  6. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636–44. https://doi.org/10.1200/JCO.2003.11.136.

    Article  CAS  PubMed  Google Scholar 

  7. Opitz I, Scherpereel A, Berghmans T, Psallidas I, Glatzer M, Rigau D, et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2020;58(1):1–24. https://doi.org/10.1093/ejcts/ezaa158.

    Article  PubMed  Google Scholar 

  8. Proto C, Signorelli D, Mallone S, Prelaj A, Lo Russo G, Imbimbo M, et al. The prognostic role of TNM staging compared with tumor volume and number of pleural sites in malignant pleural mesothelioma. Clin Lung Cancer. 2019;20(6):e652–60. https://doi.org/10.1016/j.cllc.2019.06.019.

    Article  PubMed  Google Scholar 

  9. Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, et al. Mesothelioma domain of the IASLC staging and prognostic factors committee, advisory boards and participating institutions. The IASLC mesothelioma staging project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma. J Thorac Oncol. 2016;11(12):2100–11. https://doi.org/10.1016/j.jtho.2016.09.121.

    Article  PubMed  Google Scholar 

  10. Baldini EH, Richards WG, Gill RR, Goodman BM, Winfrey OK, Eisen HM, et al. Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2015;149(5):1374–81. https://doi.org/10.1016/j.jtcvs.2014.10.128.

    Article  PubMed  PubMed Central  Google Scholar 

  11. van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881–9. https://doi.org/10.1200/JCO.20005.14.589.

    Article  CAS  PubMed  Google Scholar 

  12. Bottomley A, Gaafar R, Manegold C, Burgers S, Coens C, Legrand C, et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada Intergroup Study. J Clin Oncol. 2006;24(9):1435–42. https://doi.org/10.1200/JCO.2005.03.3027.

    Article  CAS  PubMed  Google Scholar 

  13. Arnold DT, Hooper CE, Morley A, White P, Lyburn ID, Searle J, et al. The effect of chemotherapy on health-related quality of life in mesothelioma: results from the SWAMP trial. Br J Cancer. 2015;112(7):1183–9. https://doi.org/10.1038/bjc.2015.77.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405–14. https://doi.org/10.1016/S0140-6736(15)01238-6.

    Article  CAS  PubMed  Google Scholar 

  15. Vlahu T, Vigneswaran WT. Pleurectomy and decortication. Ann Transl Med. 2017;5(11):246. https://doi.org/10.21037/atm.2017.04.03.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Cao C, Yan TD, Bannon PG, McCaughan BC. Summary of prognostic factors and patient selection for extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Surg Oncol. 2011;18(10):2973–9. https://doi.org/10.1245/s10434-011-1728-x.

    Article  PubMed  Google Scholar 

  17. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620–6. https://doi.org/10.1016/j.jtcvs.2007.10.054.

    Article  PubMed  Google Scholar 

  18. Lococo F, Torricelli F, Lang-Lazdunski L, Veronesi G, Rena O, Paci M, et al. Survival results in biphasic malignant pleural mesothelioma patients: a multicentric analysis. J Thorac Cardiovasc Surg. 2020;159(4):1584–93. https://doi.org/10.1016/j.jtcvs.2019.08.027.

    Article  CAS  PubMed  Google Scholar 

  19. Meyerhoff RR, Yang CF, Speicher PJ, Gulack BC, Hartwig MG, D’Amico TA, et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196(1):23–32. https://doi.org/10.1016/j.jss.2015.01.043.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Cao C, Tian D, Park J, Allan J, Pataky KA, Yan TD. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240–5. https://doi.org/10.1016/j.lungcan.2013.11.026.

    Article  PubMed  Google Scholar 

  21. Burt BM, Cameron RB, Mollberg NM, Kosinski AS, Schipper PH, Shrager JB, et al. Malignant pleural mesothelioma and the society of thoracic surgeons database: an analysis of surgical morbidity and mortality. J Thorac Cardiovasc Surg. 2014;148(1):30–5. https://doi.org/10.1016/j.jtcvs.2014.03.011.

    Article  PubMed  Google Scholar 

  22. Lauk O, Hoda MA, de Perrot M, Friess M, Klikovits T, Klepetko W, et al. Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions. Ann Thorac Surg. 2014;98(5):1748–54. https://doi.org/10.1016/j.athoracsur.2014.05.071.

    Article  PubMed  Google Scholar 

  23. Infante M, Morenghi E, Bottoni E, Zucali P, Rahal D, Morlacchi A, et al. Comorbidity, postoperative morbidity and survival in patients undergoing radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2016;50(6):1077–82. https://doi.org/10.1093/ejcts/ezw215.

    Article  PubMed  Google Scholar 

  24. Sharkey AJ, Tenconi S, Nakas A, Waller DA. The effects of an intentional transition from extrapleural pneumonectomy to extended pleurectomy/decortication. Eur J Cardiothorac Surg. 2016;49(6):1632–41. https://doi.org/10.1093/ejcts/ezv403.

    Article  PubMed  Google Scholar 

  25. Treasure T, Waller D, Tan C, Entwisle J, O’Brien M, O’Byrne K, et al. The mesothelioma and radical surgery randomized controlled trial: the mars feasibility study. J Thorac Oncol. 2009;4(10):1254–8. https://doi.org/10.1097/JTO.0b013e3181ae26ae.

    Article  PubMed  Google Scholar 

  26. Lim E. Mesothelioma and radical surgery. ClinicalTrials.gov Identifier NCT02040272. https://www.clinicaltrials.gov/ct2/show/NCT02040272

  27. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. MARS trialists. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763–72. https://doi.org/10.1016/S1470-2045(11)70149-8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, et al. The MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011;12(12):1093–4. https://doi.org/10.1016/S1470-2045(11)70307-2.

    Article  PubMed  Google Scholar 

  29. Utkan G, Yalçin B, Büyükçelik A, Yalçin S. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma: is it safe? J Clin Oncol. 2005;23(3):655. https://doi.org/10.1200/JCO.2005.05.259.

    Article  PubMed  Google Scholar 

  30. Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol. 2007;18(7):1196–202. https://doi.org/10.1093/annonc/mdm093.

    Article  CAS  PubMed  Google Scholar 

  31. Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer. 2007;57(1):89–95. https://doi.org/10.1016/j.lungcan.2007.02.004.

    Article  PubMed  Google Scholar 

  32. Kapeles M, Gensheimer MF, Mart DA, Sottero TL, Kusano AS, Truong A, et al. Trimodality treatment of malignant pleural mesothelioma: an institutional review. Am J Clin Oncol. 2018;41(1):30–5. https://doi.org/10.1097/COC.0000000000000225.

    Article  PubMed  Google Scholar 

  33. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007–13. https://doi.org/10.1200/JCO.2008.20.3943.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J. 2010;36(6):1362–9. https://doi.org/10.1183/09031936.00039510.

    Article  PubMed  Google Scholar 

  35. Bovolato P, Casadio C, Billè A, Ardissone F, Santambrogio L, Ratto GB, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9(3):390–6. https://doi.org/10.1097/JTO.0000000000000064.

    Article  PubMed  Google Scholar 

  36. Sharif S, Zahid I, Routledge T, Scarci M. Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg. 2011;12(6):1040–5. https://doi.org/10.1510/icvts.2010.256289.

    Article  PubMed  Google Scholar 

  37. Sugarbaker DJ, Richards WG, Bueno R. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg. 2014;260(4):577–80. https://doi.org/10.1097/SLA.0000000000000903.

    Article  PubMed  Google Scholar 

  38. Cao CQ, Yan TD, Bannon PG, McCaughan BC. A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol. 2010;5(10):1692–703. https://doi.org/10.1097/JTO.0b013e3181ed0489.

    Article  PubMed  Google Scholar 

  39. Bölükbas S, Eberlein M, Schirren J. Prospective study on functional results after lung-sparing radical pleurectomy in the management of malignant pleural mesothelioma. J Thorac Oncol. 2012;7(5):900–5. https://doi.org/10.1097/JTO.0b013e31824de2dc.

    Article  PubMed  Google Scholar 

  40. Hasegawa S. Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma. Gen Thorac Cardiovasc Surg. 2014;62(9):516–21. https://doi.org/10.1007/s11748-014-0389-7.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Lang-Lazdunski L, Bille A, Lal R, Cane P, McLean E, Landau D, et al. Pleurectomy/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma. J Thorac Oncol. 2012;7(4):737–43. https://doi.org/10.1097/JTO.0b013e31824ab6c5.

    Article  PubMed  Google Scholar 

  42. Lim E, Darlison L, Edwards J, Elliott D, Fennell DA, Popat S, et al. MARS 2 trialists. Mesothelioma and radical surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open. 2020;10(9):e038892. https://doi.org/10.1136/bmjopen-2020-038892.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Senyiğit A, Bayram H, Babayiğit C, Topçu F, Balci AE, Satici O. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases. Respiration. 2000;67(6):623–9. https://doi.org/10.1159/000056291.

    Article  PubMed  Google Scholar 

  44. Horn D, Dequanter D, Lothaire P. Palliative treatment of malignant pleural effusions. Acta Chir Belg. 2010;110(1):32–4. https://doi.org/10.1080/00015458.2010.11680561.

    Article  CAS  PubMed  Google Scholar 

  45. Thomas R, Piccolo F, Miller D, MacEachern PR, Chee AC, Huseini T, Yarmus L, Bhatnagar R, Lee HJ, Feller-Kopman D, Maskell NA, Tremblay A, Lee YCG. Intrapleural fibrinolysis for the treatment of indwelling pleural catheter-related symptomatic loculations: a multicenter observational study. Chest. 2015;148(3):746–51. https://doi.org/10.1378/chest.14-2401.

    Article  PubMed  Google Scholar 

  46. Fysh ET, Tan SK, Read CA, Lee F, McKenzie K, Olsen N, et al. Pleurodesis outcome in malignant pleural mesothelioma. Thorax. 2013;68(6):594–6. https://doi.org/10.1136/thoraxjnl-2012-203043.

    Article  PubMed  Google Scholar 

  47. Lumachi F, Mazza F, Ermani M, Chiara GB, Basso SM. Talc pleurodesis as surgical palliation of patients with malignant pleural effusion. Analysis of factors affecting survival. Anticancer Res. 2012;32(11):5071–4.

    PubMed  Google Scholar 

  48. Fysh ETH, Bielsa S, Budgeon CA, Read CA, Porcel JM, Maskell NA, et al. Predictors of clinical use of pleurodesis and/or indwelling pleural catheter therapy for malignant pleural effusion. Chest. 2015;147(6):1629–34. https://doi.org/10.1378/chest.14-1701.

    Article  PubMed  Google Scholar 

  49. Srivastava V, Dunning J, Au J. Does video-assisted thoracoscopic decortication in advanced malignant mesothelioma improve prognosis? Interact Cardiovasc Thorac Surg. 2009;8(4):454–6. https://doi.org/10.1510/icvts.2008.197160.

    Article  PubMed  Google Scholar 

  50. Rintoul RC, Ritchie AJ, Edwards JG, Waller DA, Coonar AS, Bennett M, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118–27. https://doi.org/10.1016/S0140-6736(14)60418-9.

    Article  PubMed  Google Scholar 

  51. Muir KW, Rodger JC. Cardiac tamponade as the initial presentation of malignancy: is it as rare as previously supposed? Postgrad Med J. 1994;70(828):703–7. https://doi.org/10.1136/pgmj.70.828.703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Georghiou GP, Stamler A, Sharoni E, Fichman-Horn S, Berman M, Vidne BA, et al. Video-assisted thoracoscopic pericardial window for diagnosis and management of pericardial effusions. Ann Thorac Surg. 2005;80(2):607–10. https://doi.org/10.1016/j.athoracsur.2005.02.068.

    Article  PubMed  Google Scholar 

  53. McDonald JM, Meyers BF, Guthrie TJ, Battafarano RJ, Cooper JD, Patterson GA. Comparison of open subxiphoid pericardial drainage with percutaneous catheter drainage for symptomatic pericardial effusion. Ann Thorac Surg. 2003;76(3):811–5. https://doi.org/10.1016/s0003-4975(03)00665-9.

    Article  PubMed  Google Scholar 

  54. Jama GM, Scarci M, Bowden J, Marciniak SJ. Palliative treatment for symptomatic malignant pericardial effusion†. Interact Cardiovasc Thorac Surg. 2014;19(6):1019–26. https://doi.org/10.1093/icvts/ivu267.

    Article  PubMed  Google Scholar 

  55. Janes SM, Rahman NM, Davies RJ, Lee YC. Catheter-tract metastases associated with chronic indwelling pleural catheters. Chest. 2007;131(4):1232–4. https://doi.org/10.1378/chest.06-2353.

    Article  PubMed  Google Scholar 

  56. Schwartz RM, Lieberman-Cribbin W, Wolf A, Flores RM, Taioli E. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. BMC Cancer. 2018;18(1):1188. https://doi.org/10.1186/s12885-018-5064-4.

    Article  PubMed  PubMed Central  Google Scholar 

  57. de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413–8. https://doi.org/10.1200/JCO.2008.17.5604.

    Article  CAS  PubMed  Google Scholar 

  58. Stahel RA, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16(16):1651–8. https://doi.org/10.1016/S1470-2045(15)00208-9.

    Article  PubMed  Google Scholar 

  59. Rusch VW, Rosenzweig K, Venkatraman E, Leon L, Raben A, Harrison L, et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122(4):788–95. https://doi.org/10.1067/mtc.2001.116560.

    Article  CAS  PubMed  Google Scholar 

  60. Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, et al. Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013;8(2):238–45. https://doi.org/10.1097/JTO.0b013e31827740f0.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Thieke C, Nicolay NH, Sterzing F, Hoffmann H, Roeder F, Safi S, et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol. 2015;10:267. https://doi.org/10.1186/s13014-015-0575-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Bece A, Tin MM, Martin D, Lin R, McLean J, McCaughan B. Hemithoracic radiation therapy after extrapleural pneumonectomy for malignant pleural mesothelioma: toxicity and outcomes at an Australian institution. J Med Imaging Radiat Oncol. 2015;59(3):355–62. https://doi.org/10.1111/1754-9485.12291.

    Article  PubMed  Google Scholar 

  63. Casiraghi M, Maisonneuve P, Brambilla D, Solli P, Galetta D, Petrella F, et al. Induction chemotherapy, extrapleural pneumonectomy and adjuvant radiotherapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2017;52(5):975–81. https://doi.org/10.1093/ejcts/ezx122.

    Article  PubMed  Google Scholar 

  64. Federico R, Adolfo F, Giuseppe M, Lorenzo S, Martino DT, Anna C, et al. Phase II trial of neoadjuvant pemetrexed plus cisplatin followed by surgery and radiation in the treatment of pleural mesothelioma. BMC Cancer. 2013;13:22. https://doi.org/10.1186/1471-2407-13-22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Rimner A. Pleurectomy/decortication (Neo) adjuvant chemotherapy and intensity modulated radiation therapy to the pleura in patients with locally advanced malignant pleural mesothelioma. ClinicalTrials.gov identifier NCT00715611. https://clinicaltrials.gov/ct2/show/NCT00715611

  66. Bayman N, Appel W, Ashcroft L, Baldwin DR, Bates A, Darlison L, et al. Prophylactic irradiation of tracts in patients with malignant pleural mesothelioma: an open-label, multicenter, Phase III randomized trial. J Clin Oncol. 2019;37(14):1200–8. https://doi.org/10.1200/JCO.18.01678.

    Article  CAS  PubMed  Google Scholar 

  67. Mohiuddin M, Marks J, Marks G. Management of rectal cancer: short- vs. long-course preoperative radiation. Int J Radiat Oncol Biol Phys. 2008;72(3):636–43. https://doi.org/10.1016/j.ijrobp.2008.05.069.

    Article  PubMed  Google Scholar 

  68. Chouliaras K, Senehi R, Ethun CG, Poultsides G, Grignol V, Clarke CN, et al. Role of radiation therapy for retroperitoneal sarcomas: an eight-institution study from the US Sarcoma Collaborative. J Surg Oncol. 2019;120(7):1227–34. https://doi.org/10.1002/jso.25694.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Cho BC, Feld R, Leighl N, Opitz I, Anraku M, Tsao MS, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the “SMART” approach for resectable malignant pleural mesothelioma. J Thorac Oncol. 2014;9(3):397–402. https://doi.org/10.1097/JTO.0000000000000078.

    Article  PubMed  Google Scholar 

  70. Chan WH, Sugarbaker DJ, Burt BM. Intraoperative adjuncts for malignant pleural mesothelioma. Transl Lung Cancer Res. 2017;6(3):285–94. https://doi.org/10.21037/tlcr.2017.05.04.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol. 1985;20(1):1–9. https://doi.org/10.1016/0090-8258(85)90118-0.

    Article  CAS  PubMed  Google Scholar 

  72. Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas WE, Yon JL, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97(6):845–51. https://doi.org/10.7326/0003-4819-97-6-845.

    Article  CAS  PubMed  Google Scholar 

  73. Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145(4):955–63. https://doi.org/10.1016/j.jtcvs.2012.12.037.

    Article  CAS  PubMed  Google Scholar 

  74. Friedberg JS. Radical pleurectomy and photodynamic therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1(4):472–80. https://doi.org/10.3978/j.issn.2225-319X.2012.11.14.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Friedberg JS, Culligan MJ, Mick R, Stevenson J, Hahn SM, Sterman D, et al. Radical pleurectomy and intraoperative photodynamic therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2012;93(5):1658–65. https://doi.org/10.1016/j.athoracsur.2012.02.009.

    Article  PubMed  PubMed Central  Google Scholar 

  76. Castano AP, Mroz P, Hamblin MR. Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer. 2006;6(7):535–45. https://doi.org/10.1038/nrc1894.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Friedberg JS, Simone CB 2nd, Culligan MJ, Barsky AR, Doucette A, McNulty S, et al. Extended pleurectomy-decortication-based treatment for advanced stage epithelial mesothelioma yielding a median survival of nearly three years. Ann Thorac Surg. 2017;103(3):912–9. https://doi.org/10.1016/j.athoracsur.2016.08.071.

    Article  PubMed  Google Scholar 

  78. Cengel K. Phase II trial of radical pleurectomy with or without intraoperative PDT for malignant pleural mesothelioma. ClinicalTrials.gov identifier: NCT02153229. https://clinicaltrials.gov/ct2/show/NCT02153229

  79. Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, et al. Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019;7(7):569–80. https://doi.org/10.1016/S2213-2600(19)30139-0.

    Article  CAS  PubMed  Google Scholar 

  80. Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261–73. https://doi.org/10.1016/S1470-2045(17)30446-1.

    Article  CAS  PubMed  Google Scholar 

  81. Nowak A, Lesterhuis W, Hughes B, Brown C, Kok P-S, O’Byrne K, et al. DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma—First results. J Clin Oncol. 2018;36:8503. https://doi.org/10.1200/JCO.2018.36.15_suppl.8503.

    Article  Google Scholar 

  82. Zalcman G, Peters S, Mansfield A, Jahan T, Popat S, Scherpereel A, et al. Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. J Clin Oncol. 2017;35:TPS8581. https://doi.org/10.1200/JCO.2017.35.15_suppl.TPS8581.

    Article  Google Scholar 

  83. Bristol-Myers S. A phase III, randomized, open label trial of Nivolumab in combination with ipilimumab versus pemetrexed with cisplatin or carboplatin as first line therapy in unresectable pleural mesothelioma. ClinicalTrials.gov identifier NCT02899299. https://clinicaltrials.gov/ct2/show/NCT02899299

  84. Zalcman G, Peters S, Mansfield AS, Jahan TM, Popat S, Scherpereel A, et al. Checkmate 743: a phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma. J Clin Oncol. 2017;35(15):8581.

    Article  Google Scholar 

  85. Wright K. FDA approves nivolumab plus ipilimumab for previously untreated unresectable malignant pleural mesothelioma. Oncology (Williston Park). 2020;34(11):502–3. https://doi.org/10.46883/ONC.2020.3411.0502.

    Article  PubMed  Google Scholar 

  86. Gray SG, Mutti L. Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives. Transl Lung Cancer Res. 2020;9(Suppl 1):S100–19. https://doi.org/10.21037/tlcr.2019.11.23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

No funding was obtained for this publication. The authors did not obtain any additional support and created this manuscript independently.

Funding

No specific funding was received for this work.

Author information

Authors and Affiliations

  1. Section of Thoracic Surgery, Department of Surgery, University of Michigan, Ann Arbor, MI, USA

    Taylor Kantor MD & Elliot Wakeam MD, MPH

Authors
  1. Taylor Kantor MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elliot Wakeam MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elliot Wakeam MD, MPH.

Ethics declarations

Disclosures

Taylor Kantor and Elliot Wakeam have no relevant disclosures to declare.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kantor, T., Wakeam, E. Landmark Trials in the Surgical Management of Mesothelioma. Ann Surg Oncol 28, 2037–2047 (2021). https://doi.org/10.1245/s10434-021-09589-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-021-09589-5

Search

Navigation